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This paper addresses the role of paracetamol in placebo-controlled osteoarthritis (OA) trials and the potential contribution to the
large placebo response in such trials. Paracetamol is used as rescue medication in nearly all OA placebo-controlled trials. Triggered
by the discussion about the placebo eﬀect in general and because of the lack of systematic reviews of placebo eﬀect in OA trials, a
recent meta-analysis examined the placebo eﬀect and its potential determinants in the treatment of OA, as the main result came
out that placebo is very eﬀective in the treatment of OA, especially for pain, stiﬀness, and self-reported function. However, mostly
limited data are available from published OA trials on the starting dose, ﬁnal dose, dose over time of paracetamol use, and the
percentage of patients who used rescue medication during the study. Paracetamol may be an important additional simulated eﬀect
of placebo administration mimicking the true placebo eﬀect and thus a missing link contributing partially to the large placebo
responseinOAtrials.Therefore,thepositiveeﬀectofparacetamolonsymptomreliefaswellastheneedforstandardizedrecording
of rescue medication should be taken into account when designing, executing, and interpreting placebo-controlled OA studies.
1.Introduction
Osteoarthritis (OA) is by far the commonest, chronic,
musculoskeletal disorder characterized by joint pain, stiﬀ-
ness, loss of motion, and impaired quality of life aﬄicting
an increasingly older population. There is no curative
treatment for this disease despite availability of a large
number of therapeutic options, including nonpharmacolog-
ical, pharmacological, and surgical therapies. Symptomatic
treatment to relieve pain and incapacity can be obtained
with analgesics such as paracetamol or the more eﬀective
nonsteroidal anti-inﬂammatory drugs (NSAIDs). Current
guidelines emphasize paracetamol as the ﬁrst-line therapy,
when pharmacological agents are needed [1–4]. Paracetamol
(350mg up to 4000mg) is used as rescue medication in
nearly all OA trials. It has been speculated whether placebo
is eﬀective for OA and which factors may determine the
size of such an eﬀect (as discussed by Zhang et al. [5]).
This is a common discussion point when a randomised
controlled trial (RCT) fails to demonstrate superiority of
active treatment over placebo. The present paper addresses
the role of paracetamol as rescue medication in OA trials and
the potential contribution to the large placebo response in
such trials.
2.Paracetamol inOsteoarthritis
Paracetamol (acetaminophen) is a simple analgesic used
in OA for decades that has both analgesic and antipyretic
actions. It has a narrow therapeutic window but in recom-
mended doses (1g three to four times daily) is of favourable
eﬃcacy and very safe. Studies comparing paracetamol to
placebo show that people with OA who take paracetamol
have less pain (when resting, moving, sleeping, and overall)
and feel better overall than people who take a placebo
(as discussed by Towheed et al. [6]). A meta-analysis of
randomised controlled trials reported that paracetamol is
eﬀectiveinrelievingpainduetoOAwhenusedinaﬁxeddose
between 2000mg and 4000mg and that paracetamol has a
higher response rate than placebo [7]. The eﬀect size (ES) of
0.21 is small but statistically signiﬁcant, although the eﬃcacy
is inferior to that of NSAIDs. A recent Cochrane systemic
review concluded that paracetamol is superior to placebo in
OA with an improvement from baseline of 5%, an absolute2 Pain Research and Treatment
change of 4 points on a 0 to 100 pain scale, and a number
n e e d e dt ot r e a t( N N T )r a n g i n gf r o m4t o1 6[ 6].
One RCT showed that paracetamol could be used eﬀec-
tively in doses of up to 2600mg/day for two years without
signiﬁcant adverse outcomes [8]. However, there has been a
controversy about the gastrointestinal safety of paracetamol,
particularlyascomparedwithNSAIDsbecauseoffewreports
suggesting possible GI side eﬀects from paracetamol [9].
Nevertheless, these data have not been replicated and a
recent meta-analysis of RCTs, which avoids channelling bias,
showed no more GI symptoms from paracetamol than from
placebo [4]. Altogether, the clinical evidence supports the
better overall gastrointestinal safety proﬁle of paracetamol
compared with nonselective NSAIDs.
Current European evidence-based recommendations for
the management of knee, hip, and hand OA devised by
the European League against Rheumatism (EULAR) state
that “because of its eﬃcacy and safety paracetamol (up
to 4g/day) is the oral analgesic of ﬁrst choice and, if
successful, is the preferred long term oral analgesic” [2–4].
This recommendation is based on evidence (level 1B) that
paracetamol is eﬀective in the treatment of knee OA and that
in many patients it is comparable with ibuprofen in the short
term and almost as eﬃcacious as naproxen. There is also
evidence (level 1B) that paracetamol can be taken safely over
the long term. Thus, in agreement paracetamol is available
over the counter and frequently used as self-medication for
the treatment of mild to moderate pain.
3.PlaceboEffectsinOsteoarthritis
Placebo is a “sham drug” containing only starch or other
inert ﬁllers without any pharmacologically active substance,
which is externally indistinguishable from a true drug. As
ineﬀective substances, placebo is primarily used nowadays
within the double-blind RCT setting. The placebo itself
cannot trigger any pharmacological eﬀect, and therefore
their role is to allow a control group to be treated without
therapeutic eﬀect. However, other subjective and psycholog-
ical eﬀects are possible. The term “placebo eﬀect” means this
eﬀect of the administration of a placebo.
The placebo eﬀect has long been a source of specu-
lation. A common conception was that eﬀects of placebo
interventions are large such as documented by numerous
randomized trials in a wide range of clinical conditions.
However, this prevailing opinion was questioned when
Hr´ objartsson and Gøtzsche reported a meta-analysis of
114 randomized trials, across 40 clinical conditions [10].
The challenging results indicated a signiﬁcant, but modest,
eﬀect of placebo on continuous subjective outcomes. Pain
was the only condition for which a statistically signiﬁcant
eﬀect of placebo could be observed. An updated analysis
including a new sample of trials reproduced the key result
of a statistically signiﬁcant placebo eﬀect for trials with
patient-reported continuous outcomes, especially for pain
[11]. Further evidence from placebo analgesia experiments
strongly supports the reality of the placebo eﬀect in pain
trials [12]. Vase et al. [12] compared the clinical trials of pain
treatment included in the meta-analysis of Hr´ objartsson and
Gøtzsche [10] with experimental studies evaluating placebo
analgesia that included a no-treatment condition. In the
clinical trials, patients were told that they would receive
either active treatment or a disguised placebo, whereas in
the studies of placebo analgesia patients receiving placebo
were told that they would receive a powerful painkiller.
Consequently, the eﬀect of placebo analgesia is markedly
greater when patients are told that a placebo treatment is a
powerful painkiller than when they are told that they may
receive either a powerful painkiller or placebo and obviously
depending on the informational context and diﬀerent verbal
instructions about certain and uncertain expectations of
analgesia [13]. Altogether, the observed placebo eﬀect in
RCT has real and apparent components [14]. True eﬀects of
placebo administration are unconscious conditioning, con-
scious expectations, mode of administration and context of
administration, the physician’s personality, and the doctor-
patient relationship. However, simulated eﬀects such as the
natural course of the underlying disease and the statistical
phenomenon of regression to the mean can mimic the true
placebo eﬀects.
Triggered by the discussion about the placebo eﬀect
in general and because of the lack of a systematic review
of placebo eﬀect in RCTs, Zhang and colleagues recently
performed a meta-analysis to examine the placebo eﬀect and
its potential determinants in the treatment of OA [5]. The
study aim was to determine whether placebo has clinical
eﬀects in the treatment of OA, by comparing outcomes
at baseline and endpoint and by comparing placebo with
untreated control. In addition, they examined possible
determinants of the placebo eﬀect in OA. For their analysis,
Zhang et al. deﬁned the placebo eﬀect as the change from
baseline to endpoint in the placebo group, estimated as the
eﬀect size (ES). The ES as found in the placebo group was
compared with the ES obtained from untreated controls. As
the main result came out that placebo is very eﬀective in
the treatment of OA, especially for pain (ES 0.51), stiﬀness
(ES 0.43), and self-reported function (ES 0.49) [5]. The ES
for pain in the untreated controls was 0.03. The baseline
severity, the expected strength of the treatment, the route
of delivery, and the sample size appeared to be important
determinants of the magnitude of eﬀect [5]. Further factors
such as reporting bias (a patient might feel obliged to report
an eﬀect when there really is not any: “I will please”),
publication bias, and concomitant treatment might play a
role as well (as discussed by Bijlsma and Welsing [15]).
Especially, rescue medication is such a factor, which might
interfere with the true placebo eﬀect.
4.Rescue MedicationinOsteoarthritis Trials
Many patients with OA who are recruited for trials are
likely to have exacerbations of symptoms (ﬂares) which
require concomitant treatment during the study, irrespective
of the type of study design used. Such rescue medications
sometimes called “escape medications” are medicines, which
the European Medicines Agency (EMA) clinical trial guid-
ance covers under the term Non-Investigational Medicinal
Products (NIMPs) [16] to be presented in the study protocolPain Research and Treatment 3
under concomitant medication and secondary endpoints.
Rescue medication allows patients to continue in the clinical
trial when the eﬃcacy of the Investigational Medicinal
Product (IMP) is not satisfactory, for example, placebo
controlled clinical trials where a standard treatment is
available or dose response studies where lower doses might
be ineﬀective [16]. It is possible to provide single blind
rescue medication as well as open-label rescue medication.
However, rescue medication use inﬂuences the evaluation
of symptoms and, thus, complicates the interpretation of
results. The main problem of using rescue medication is
that alleviated and reduced symptoms can bias the diﬀerence
in outcome between the placebo and the active treatment
group.Furthermore,itisdiﬃculttodeﬁnetheoptimumdose
when rescue medication is used. Thus, it is crucial to instruct
the patients to use the rescue medication only if necessary.
In OA trials usually short-acting analgesics such as
paracetamol or sometimes ibuprofen are given to control
acute episodes of breakthrough pain in a patient on a pain
management regimen. For example, in a trial on retention
on treatment with lumiracoxib and celecoxib, in which a
maximum dose of 2g paracetamol was permitted, rescue
medication was used by 79.5% to 81.3% of the patients
[17]. The recent meta-analysis examining the placebo eﬀect
and its potential determinants in the treatment of OA
identiﬁed only 15 trials out of 193 trials, which did not allow
rescue medications [5]. The EMA clinical trial guidance
recommends exposing to rescue medications only those
patients assigned to placebo or to an ineﬀective dose
of the treatment; this should minimize the possibility of
interactions with the test medicine [16]. According US Food
and Drug Administration (FDA) guidance, the eﬀects of
confounders such as rescue medication and assistive devices
should be standardized in the protocol and in the analysis of
OA trials [18]. The EMA demand in the guideline on clinical
investigation of medicinal products used in the treatment
of osteoarthritis that rescue treatment (including physical
therapy) should be standardised, monitored, and carefully
recorded for each individual patient [19]. The time points of
endpointassessmentshouldbeappropriatelychosentoavoid
confounding eﬀects of the rescue medication.
Paracetamol is the rescue medication in most placebo-
controlled OA trials. Therefore, the question arises if the
guidelines and recommendations are followed. A look into
recently published OA trials retrieved by PubMed shows a
considerable diversity in dosing, recording, and monitoring
of paracetamol use as well as an even larger variability in
reportingstudyresults(Table 1)[20–29].Thedosepermitted
varies between 325mg per tablet with 1-2 tablets to be
taken every 4–6 hours up to 4g daily. Only in two studies,
patientswereinstructednottotakethisdrugwithin24hours
and 48 hours, respectively, of a follow-up visit to allow for
accurate measurement of their current pain levels. Rescue
medication was in one study the main outcome and in the
others a secondary endpoint or not deﬁned as an out-come
parameter. The number of tablets used or the averaged dose
was shown in only four trials. Two trials presented not at
all results. Altogether, the reporting of rescue medication
with paracetamol in OA trials is far from fulﬁlling the
recommendations and limits the validation of the impact on
the placebo eﬀect.
Interestingly, neither the two publications [5, 15] dealing
with the placebo eﬀe c ti nO At r i a l sn o rm o s tr e c e n te x t e n s i v e
reviews [30, 31] on the placebo eﬀect in general including
pain studies discussed the possible impact of paracetamol as
rescue medication on the observed placebo eﬀect.
5.Paracetamol andPlaceboEffect:
A MissingLink?
Individuals with greater baseline level of OA pain or use
of a limited form of treatment would be more likely
to utilize rescue therapy. This was the case in the Glu-
cosamine/chondroitin Arthritis Intervention Trial (GAIT),
which allowed up to 4000mg of paracetamol daily as rescue
analgesia. Patients with moderate-to-severe pain used 1.9
± 1.9 to 2.5 ± 2.2 tablets (500mg) per day at the end of
followup compared to 1.4 ± 1 . 6t o1 . 7± 1.8 tablets in
patients with mild pain [32] .T h ep r i m a r yo u t c o m em e a s u r e
was a response to treatment, deﬁned as a 20% decrease in
the summed score for the Western Ontario and McMaster
Universities (WOMAC) pain subscale. This outcome was
reached in 64% of the glucosamine group, 65% of the
chondroitin sulphate group, 67% of the combination, 70%
of the celecoxib, and 60% of the placebo group. Overall,
diﬀerences between placebo and the active treatments were
relatively small and reached signiﬁcance only in comparison
with celecoxib. The high rates of response to placebo may
relate, in part, to patients’ biases and expectations. Another
important factor might be the enrollment of patients mostly
having relatively mild knee pain at baseline as compared
with classic OA studies with a ﬂare design (as discussed by
Clegg et al. [32]). Additionally, one may speculate that the
use of paracetamol rescue medication in the patients with
mild symptoms importantly contributed to the high rate of
pain release in the placebo group.
Altogether, paracetamol may be a missing link to explain
at least partially the high placebo rate in OA trials not seen
in other medical conditions [10]. Indeed, Zhang et al. [5]
reported in their meta-analysis that only 15 trials analyzed
did not allow rescue medications. The eﬀect size was 0.71
without rescue medication compared to 0.51 in all trials
(n = 193) and 0.03 in trials with untreated controls (n =
14), which suggest that rescue medication can mask the
eﬃcacy of the active treatment. However, rescue medication
use is not assessed sequentially along with other variables in
OA trials and mostly limited or no data are available from
published trials on the starting dose, ﬁnal dose, dose over
time of paracetamol rescue medication, and the percentage
of patients who used rescue medication during the study.
Therefore, there is a need to collect comprehensive data
on active use of rescue medication from studies in OA
and to evaluate further the contribution of paracetamol as
one determinant of placebo eﬀect. Like the natural course
of disease and regression to the mean paracetamol may
be an important additional simulated eﬀect of placebo
administration mimicking the true placebo eﬀect.4 Pain Research and Treatment
Table 1: Paracetamol rescue medication in randomised controlled osteoarthritis trials in selected recent publications.
Trial Doses allowed (mg) Primary or secondary
endpoint Results Remarks
Frestedt et al.
[20]
325mg per tablet with 1-2
tablets to be taken every 4–6
hours as needed for pain
No
No signiﬁcant diﬀerences
between the two groups for
rescue medication
consumption at any single
time point or over time
No ﬁgures given
Karlsson et al.
[21]
≤4000mg/day could be taken
as for unacceptable pain for
more than 24 hours
No
Rescue medication usage was
signiﬁcantly better than under
placebo
No ﬁgures given
Jacquet et al.
[22]
Tablets equivalent to 500mg
paracetamol alone or
combined with weak opiates
(e.g., coproxamol or
coparein)
Main outcome measure
500mg paracetamol
equivalent tablets per week
(PET/week) measured each
month
Single-component
Paracetamol (number of
users, tablets/week ± SD)
Phytalgic 12 (21 ± 14.7)
Placebo 15 (15.4 ± 10.4)
Add-on study to the usual
symptomatic medication
(analgesics and/or NSAIDs)
Kr¨ uger et al.
[23]
500mg tablets; intake was
permitted if necessary due to
pain but not 48 hours before
visits
Secondary endpoint,
recorded daily by the
patient in the diary and
checked by the physician at
each visit (pill counting)
Low acetaminophen
consumption; diﬀerences
between the groups not
signiﬁcant
No ﬁgures given
Puopolo et al.
[24]
For breakthrough pain, if
needed; no dose reported
Secondary endpoint; use
was determined by tablet
counts
Patients treated with
etoricoxib or ibuprofen used
signiﬁcantly less paracetamol
than those receiving placebo
for breakthrough pain
Paracetamol use in the
etoricoxib and ibuprofen
groups was similar
Figures not listed in the
table of the key secondary
results
Reginster et al.
[25]
325mg tablets; use was
restricted (it was not
permitted during the initial 2
weeks of treatment) and
recorded
No No data shown
Sawitzke et al.
[26]
Up to 4g daily could be
taken, but patients were
instructed not to take this
drug within 24h of a
follow-up visit to allow for
accurate measurement of
their current pain levels
No
The use of paracetamol
averaged 570mg daily. The
lowest use was in the celecoxib
(465mg) group and the
highest use in the placebo
group (645mg)
Rank order of rescue drug
use (least to greatest)
exactly paralleled to that of
the primary eﬃcacy
outcome
Schnitzer et al.
[27]
500mg tablets for use in case
of increased OA pain, with a
maximum accepted dose of
2000mg/day
Additional eﬃcacy
measures
Average daily tablets use in the
placebo group 1.77 versus 1.33
to 1.43 in the naproxcinod
groups and 1.34 in the
naproxen group
Yang et al. [28] Maximum of 4g/day No No data shown
A s k e dt os t o pa n a l g e s i c sa t
least 1 week before
completing the
questionnaires and visiting
their treating orthopaedic
surgeon
Thorne et al.
[29]
325mg to 650mg every 4h to
6h as required
Secondary end point;
compared for each
treatment, based on the
average daily consumption,
and was summarized each
week
Signiﬁcantly greater use
during the placebo phase (3.4
± 3.6 tablets/day) than during
the CR tramadol phase (2.4 ±
3.1 tablets/day)Pain Research and Treatment 5
6. Conclusion andFutureDirections
Paracetamol (350mg up to 4000mg) is used as rescue
medication in nearly all OA trials. Rescue medication use
is not assessed sequentially along with other variables in
OA trials. Mostly limited or no data are available from
published trials on the starting dose, ﬁnal dose, dose over
time of paracetamol rescue medication, and the percentage
of patients who used rescue medication during the study.
Paracetamolmaybeamissinglinktoexplainatleastpartially
the large placebo response in OA trials not seen in other
medical conditions except pain studies. The use of rescue
medication with paracetamol may play an important role
in the interpretation of results of OA trials. Therefore,
future OA trials will require the meticulous recording of
paracetamol medication use in order to assure homogeneity.
Electronic systems such as the Medication Event Monitoring
System may aid in recording the consumption of paraceta-
mol objectively [33]. Symptoms and the use of paracetamol
should be assessed in a consistent manner, as both are
interrelated outcome measures. It appears vital to ﬁnd a
consensus on a standard procedure for evaluating the use of
paracetamol as rescue medication in order to draw correct
conclusions from placebo-controlled OA trials.
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